AI-generated summary
The authors reviewed randomized studies and meta-analyses from 2017 to 2022 on intense pulsed light for meibomian gland dysfunction. They report improvements in symptoms and objective measures, but note that benefits may fade by six months and repeat sessions may be needed. The authors conclude that the treatment is best viewed as an adjuvant option rather than first-line therapy, and that more evidence is required.
- Who or what was studied
- Patients with meibomian gland dysfunction (dry eye disease)
- Limits stated in the abstract
- The abstract states that more evidence is needed, that the optimal treatment modality remains unknown, and that longer follow-up periods are required.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on dovepress.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Dry eye, Meta-analysis. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.